Hunter Hall Global Value Limited Monthly Performance Report for July
Says
Australian liver cancer treatment company Sirtex rose 34% over the month after delivering outstanding June quarterly results and 2009 financial year results. Product revenue rose 72% for the year to June 2009, to exceed $65.6m, with European and U.S sales growing 117% and 28% respectively. Operational cash flow rose to $20m, up 426% on the previous corresponding period, while net profit before tax surged 640%. With very pleasing momentum, a strong balance sheet, nil borrowings and rising cash flow, we believe Sirtex has a strong outlook.
